Get the latest news, insights, and market updates on NGNE (Neurogene Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK, November 06, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental dis Nov 6, 2025 - $NGNE
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, November 05, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 1,185 shares of the Company’s common stock to one new employee (the "Inducement Grant") on November 4, 2025 (the "Grant Date"). The Inducem Nov 5, 2025 - $NGNE
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
NEW YORK, October 09, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the Company has completed discussions with the U.S. Food and Drug Administration (FDA) on its Embolden™ registrational trial protocol and plans to initiate dosing in the fourth quarter of 2025. In response to strong interest from the Rett syndrome community, the trial is expected to en Oct 9, 2025 - $NGNE
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
NEW YORK, October 08, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Oct 8, 2025 - $NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, October 03, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of the Company’s common stock to four new employees (the "Inducement Grants") on October 1, 2025 (the "Grant Date"). The Induce Oct 3, 2025 - $NGNE
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
The biotech Rocket Pharmaceuticals said the Food and Drug Administration would allow it to continue a gene therapy trial the agency had put on hold in late May, when a patient in the trial died. In the following months, investor enthusiasm for gene therapies waned even further, as what was once the biggest idea in biotech delivered even more disappointments and safety worries. Rocket’s relatively quick reprieve is good news for the stock, and suggests that the FDA remains actively supportive of gene therapy development. Aug 20, 2025 - $NGNE
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
NEW YORK, August 11, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2025 financial results and highlighted recent corporate updates. Aug 11, 2025 - $NGNE
Neurogene: Q2 Earnings Snapshot
NEW YORK (AP) — Neurogene Inc. NGNE) on Monday reported a loss of $22 million in its second quarter. On a per-share basis, the New York-based company said it had a loss of $1.05. Aug 11, 2025 - $NGNE
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK, June 30, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced details of Embolden™, the Company’s registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older. The Company has written agreement from the U.S. Food and Drug Administration (FDA) on key asp Jun 30, 2025 - $NGNE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple